凝集素靶向偶联物增强抗菌光动力疗法克服牙周炎生物膜屏障
本研究将光敏剂玫瑰红与凝集素伴刀豆球蛋白A偶联(ConA-RB),在临床相关蓝光照射下评估其对四种牙周病原菌的抗菌及抗生物膜活性,并检测对人牙龈成纤维细胞的生物相容性。结果显示ConA-RB较游离玫瑰红显著增强抗菌抗生物膜效果,归因于细菌摄取提高约4倍,同时保持良好生物相容性。结论认为ConA-RB是有前景的靶向aPDT平台。
要点
- ConA-RB通过凝集素-碳水化合物识别使细菌摄取提高约4倍。
- ConA-RB较游离玫瑰红显著增强抗菌和抗生物膜活性。
- ConA-RB在测试细胞模型中保持良好生物相容性。
核心结论
- ConA-RB生物偶联物是强效、靶向且生物相容的aPDT平台,可实质性克服生物膜屏障。
- 该策略有望改善牙周炎临床管理,尤其对常规治疗抵抗的病例。
研究设计与样本
- 将光敏剂玫瑰红与凝集素伴刀豆球蛋白A偶联合成ConA-RB,并经光谱学确认。
- 在临床相关蓝光照射下评估对牙龈卟啉单胞菌、伴放线聚集杆菌、具核梭杆菌和中间普雷沃菌的抗菌及抗生物膜活性。
- 检测细菌摄取、活力和膜损伤,并评估对人牙龈成纤维细胞的短期和长期生物相容性。
主要发现
- ConA-RB较游离玫瑰红表现出显著更优的抗菌和抗生物膜活性。
- 细菌摄取提高约4倍,由特异性凝集素-碳水化合物识别介导,导致局部活性氧生成增强和严重膜损伤。
- ConA-RB有效抑制生物膜形成并显著破坏体外成熟生物膜,同时在测试细胞模型中保持良好生物相容性。
临床怎么用
- 靶向光动力疗法可精确根除深部牙周病原菌并破坏生物膜,且不引起牙龈组织急性细胞毒性。
- 该平台有潜力提高牙周炎治疗效果,尤其适用于常规治疗抵抗的病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To address the limited efficacy of conventional antimicrobials against periodontal biofilms by developing a targeted antimicrobial photodynamic therapy (aPDT) platform and evaluating its activity against key periodontal pathogens. METHODS: The photosensitizer Rose Bengal was conjugated to the lectin Concanavalin A (ConA-RB). Its synthesis was spectroscopically confirmed. Antibacterial and antibiofilm activity against Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, and Prevotella intermedia was assessed following clinically relevant blue light irradiation, including bacterial uptake, viability, and membrane damage. Biocompatibility with human gingival fibroblasts was also evaluated following both short-term and prolonged exposure. RESULTS: ConA-RB exhibited significantly superior antibacterial and antibiofilm activity compared to free Rose Bengal. This was attributed to an approximate 4-fold increase in bacterial uptake, mediated by specific lectin-carbohydrate recognition, leading to enhanced localized reactive oxygen species generation and profound membrane damage. ConA-RB effectively inhibited biofilm formation and significantly disrupted mature in vitro biofilms while maintaining favorable biocompatibility in tested cell models. CONCLUSIONS: The ConA-RB bioconjugate is a potent, targeted, and biocompatible aPDT platform that substantially overcomes biofilm barriers. It represents a promising translational strategy for improving the clinical management of periodontitis. CLINICAL SIGNIFICANCE: By leveraging targeted photodynamic therapy, this ConA-RB platform offers a precise method to eradicate deep-seated periodontal pathogens and disrupt biofilms without inducing acute cytotoxicity in gingival tissues. This approach holds significant potential to enhance clinical outcomes in periodontitis treatment, particularly in cases resistant to conventional therapy.
引用
- Tang W, Zhang Y, Zhang J, et al. Overcoming Biofilm Barriers in Periodontitis: A Lectin-Targeted Conjugate for Enhanced Antimicrobial Photodynamic Therapy. J Dent. 2026. PMID: 42167474. doi:10.1016/j.jdent.2026.106778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。